SAREUM HOLDINGS PLC (SAR) — Unaudited financial results for the six months ended 31 December 2025

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the SAREUM HOLDINGS PLC Interim Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the q and a tab situated on the right hand corner of your screen. Just simply type in your questions and press send. Before we begin, I would like to submit the following poll. And I would now like to hand you over to executive chairman, doctor Steven Parker. Good afternoon to you, sir. Hello, and good afternoon to everybody on the call. Thank you for joining us. Today, we announced, as you know, the unaudited interim results for the six months to the thirty first of December last year, and we will take the opportunity as well as looking at those numbers to give you an update on the progress that we're making. There is, of course, the usual disclaimer. Do please remember that we will be talking about forward looking events, which may or may not happen or may or may not happen to the extent that we're describing. So that's for usual, but it's as well to remind you. Just then to remind you about the company, we, we have the three programs, tick to JAK1, eighteen oh one and eighteen oh two, and the, JAK1 inhibitor, SRA737. And we will be talking at greater or lesser length about all of those today. During the period, or since the period, I should say, we have restarted the phase two enabling tox program for 1801 with a new leading global CRO. As we were able to say this morning, all subjects have commenced dosing in that study. As you know, we were unfortunately had to discontinue the previous study with a different CRO, after the unexpected findings that came about there. We have so that unfortunately set us back about six months. T...